Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (211-220 of 372) with videos related to

Pageof 38
Sort By:
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 8, 2022
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019Hendrik Streeck, Klaus Jansen, Trevor A Crowell, et al.
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Ebiomedicine|November 8, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studyManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Journal of Virology|April 12, 2013
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trialGustavo H Kijak, Sodsai Tovanabutra, Supachai Rerks-Ngarm, et al.
Science Translational Medicine|February 17, 2017
Delayed differentiation of potent effector CD8<sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infectionHiroshi Takata, Supranee Buranapraditkun, Cari Kessing, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targetingManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Pageof 38

Showing results (211-220 of 372) with videos related to

Sort By:
Pageof 38
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 8, 2022
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019Hendrik Streeck, Klaus Jansen, Trevor A Crowell, et al.
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Ebiomedicine|November 8, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studyManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Journal of Virology|April 12, 2013
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trialGustavo H Kijak, Sodsai Tovanabutra, Supachai Rerks-Ngarm, et al.
Science Translational Medicine|February 17, 2017
Delayed differentiation of potent effector CD8<sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infectionHiroshi Takata, Supranee Buranapraditkun, Cari Kessing, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targetingManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Pageof 38